Change in Sculptra's Patient Assistance Program

[Guest guest]

Dear :

I'm sorry I missed your call earlier this week. As mentioned briefly in my voice mail message, Dermik Laboratories, now a business of sanofi-aventis U.S. LLC, is making a small administrative change in our distribution procedures for the Sculptra® Patient Access Program (PAP). This will become effective July 1, 2006, and below is a brief explanation of the changes.

Patients who meet the PAP requirements will receive up to two kits (four vials) sent directly to the physician on their behalf for their initial treatment session(s). Following the initial treatment session(s) and based on approval of subsequent applications, one kit per each additional application will be sent to the healthcare provider on behalf of the patient.

It is important to note that all terms regarding eligibility, enrollment and access to program benefits for patients with HIV-associated lipoatrophy remain the same. The only change has been in the distribution process as we have learned over the duration of the program that up to two kits for initial treatment and one kit for subsequent treatment session(s) tends to meet patient needs.

We thank you for your valuable assistance in helping to make the PAP a success and able to reach those patients with HIV-associated facial lipoatrophy in need. Please note that Dermik remains committed to the PAP program and we will continue to provide access to patients in need of assistance.

Should you have any questions please feel free to contact me. I hope we have a chance to speak by telephone sometime soon.

Sincerely,

Terri Pedone US Product & Scientific Communications sanofi-aventis

Regards, Vergelsalvagetherapies dot org